Other equities analysts have also recently issued research reports about the stock. BidaskClub cut shares of BioCryst Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Thursday, January 31st. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, March 11th. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the stock an equal weight rating in a research report on Tuesday, April 2nd. Finally, JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock a market outperform rating in a research report on Tuesday, April 2nd. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $12.00.
Shares of BCRX opened at $3.44 on Wednesday. The company has a current ratio of 1.77, a quick ratio of 1.76 and a debt-to-equity ratio of 2.38. The firm has a market cap of $383.89 million, a price-to-earnings ratio of -3.51 and a beta of 1.71. BioCryst Pharmaceuticals has a 12 month low of $3.10 and a 12 month high of $9.95.
In related news, CFO Thomas R. Staab II sold 7,750 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $7.30, for a total value of $56,575.00. Following the sale, the chief financial officer now owns 140,426 shares in the company, valued at approximately $1,025,109.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas R. Staab II sold 7,500 shares of the company’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $8.81, for a total transaction of $66,075.00. Following the completion of the sale, the insider now owns 140,176 shares in the company, valued at approximately $1,234,950.56. The disclosure for this sale can be found here. Insiders have sold a total of 75,000 shares of company stock worth $583,298 in the last three months. Insiders own 5.20% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlueMountain Capital Management LLC purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at about $72,000. Paloma Partners Management Co purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $84,000. Great West Life Assurance Co. Can increased its stake in BioCryst Pharmaceuticals by 82.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 13,336 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 6,036 shares during the last quarter. Amalgamated Bank purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $122,000. Finally, Summit Securities Group LLC purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at about $132,000. Institutional investors own 92.26% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
See Also: What is a Swap?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.